NASDAQ:ARDX Ardelyx (ARDX) Stock Forecast, Price & News $3.52 +0.02 (+0.57%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$3.40▼$3.5650-Day Range$3.23▼$4.9552-Week Range$0.49▼$5.13Volume2.95 million shsAverage Volume5.58 million shsMarket Capitalization$754.91 millionP/E RatioN/ADividend YieldN/APrice Target$6.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ardelyx MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside77.6% Upside$6.25 Price TargetShort InterestHealthy7.78% of Shares Sold ShortDividend StrengthN/ASustainability-1.32Upright™ Environmental ScoreNews Sentiment0.69Based on 4 Articles This WeekInsider TradingSelling Shares$69,647 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.43) to ($0.01) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.44 out of 5 starsMedical Sector156th out of 983 stocksPharmaceutical Preparations Industry68th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingArdelyx has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, Ardelyx has a forecasted upside of 77.6% from its current price of $3.52.Amount of Analyst CoverageArdelyx has only been the subject of 1 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted7.78% of the outstanding shares of Ardelyx have been sold short.Short Interest Ratio / Days to CoverArdelyx has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ardelyx has recently decreased by 8.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldArdelyx does not currently pay a dividend.Dividend GrowthArdelyx does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreArdelyx has received a 66.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physical health" and "Constipation medication (A06)" products. See details.Environmental SustainabilityThe Environmental Impact score for Ardelyx is -1.32. Previous Next 2.6 News and Social Media Coverage News SentimentArdelyx has a news sentiment score of 0.69. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Ardelyx this week, compared to 3 articles on an average week.Search InterestOnly 47 people have searched for ARDX on MarketBeat in the last 30 days. This is a decrease of -34% compared to the previous 30 days.MarketBeat FollowsOnly 14 people have added Ardelyx to their MarketBeat watchlist in the last 30 days. This is a decrease of -30% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ardelyx insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $69,647.00 in company stock.Percentage Held by InsidersOnly 5.50% of the stock of Ardelyx is held by insiders.Percentage Held by Institutions40.44% of the stock of Ardelyx is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ardelyx are expected to grow in the coming year, from ($0.43) to ($0.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ardelyx is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ardelyx is -8.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArdelyx has a P/B Ratio of 6.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ardelyx (NASDAQ:ARDX) StockArdelyx, Inc. is a biopharmaceutical company. It engages in the research, development, and commercialization of medicine for the treatment of cardiorenal diseases. Its product portfolio includes tenapanor, which is an experimental medication that works exclusively in the gut and is in late-stage clinical development. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet on October 17, 2007 and is headquartered in Waltham, MA.Read More Receive ARDX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ardelyx and its competitors with MarketBeat's FREE daily newsletter. Email Address ARDX Stock News HeadlinesMay 31, 2023 | finance.yahoo.comArdelyx to Present at the Jefferies 2023 Healthcare ConferenceMay 29, 2023 | americanbankingnews.comShort Interest in Ardelyx, Inc. (NASDAQ:ARDX) Decreases By 8.5%June 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 28, 2023 | americanbankingnews.comInsider Selling: Ardelyx, Inc. (NASDAQ:ARDX) CFO Sells $10,486.45 in StockMay 28, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Shares Gap Down Following Insider SellingMay 27, 2023 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) CEO Sells $41,453.05 in StockMay 22, 2023 | uk.news.yahoo.comArdelyx Insiders Land Bargain With Gains Of US$1.1mMay 22, 2023 | finance.yahoo.comArdelyx Insiders Land Bargain With Gains Of US$1.1m \June 4, 2023 | Legacy Research (Affiliate) (Ad)“Amazon Loophole” could hand you $28,544 in “royalty” payoutsThanks to a little-known IRS loophole… Regular Americans can collect up to $28,544 (or more) in payouts from what Brad Thomas calls the “Amazon secret royalty program…” See how to collect the next payout before the strict cutoff deadline.May 18, 2023 | seekingalpha.comArdelyx: Final Countdown BeginsMay 17, 2023 | finance.yahoo.comArdelyx Announces FDA Acceptance and Six-Month Review for Resubmission of its New Drug Application of XPHOZAH® (tenapanor)May 13, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Downgraded by StockNews.com to HoldMay 9, 2023 | finance.yahoo.comArdelyx Presents Positive Data at DDW 2023 on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in AdultsMay 9, 2023 | americanbankingnews.comWedbush Analysts Cut Earnings Estimates for Ardelyx, Inc. (NASDAQ:ARDX)May 6, 2023 | finance.yahoo.comRetail investors account for 60% of Ardelyx, Inc.'s (NASDAQ:ARDX) ownership, while institutions account for 38%May 4, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Upgraded to "Buy" at StockNews.comMay 2, 2023 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Sees Significant Growth in Short InterestMay 1, 2023 | finance.yahoo.comArdelyx Announces Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with IBS-C, to be Presented at the 2023 Digestive Disease Week ConferenceMay 1, 2023 | americanbankingnews.comArdelyx (ARDX) Set to Announce Earnings on WednesdayApril 27, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Upgraded by StockNews.com to BuyApril 26, 2023 | finance.yahoo.comArdelyx to Report First Quarter 2023 Financial Results and Provide Business Update on May 3, 2023April 24, 2023 | seekingalpha.comArdelyx: Underappreciated Biotech With Potential FDA Approval On DeckApril 21, 2023 | americanbankingnews.comWedbush Weighs in on Ardelyx, Inc.'s Q2 2023 Earnings (NASDAQ:ARDX)April 20, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Price Target Raised to $7.00April 20, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Shares Gap Up After Analyst UpgradeApril 19, 2023 | americanbankingnews.comArdelyx, Inc. (NASDAQ:ARDX) Short Interest Up 36.4% in MarchApril 19, 2023 | americanbankingnews.comArdelyx (NASDAQ:ARDX) Reaches New 12-Month High Following Analyst UpgradeSee More Headlines ARDX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ARDX Company Calendar Last Earnings5/03/2023Today6/03/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ARDX CUSIPN/A CIK1437402 Webwww.ardelyx.com Phone(510) 745-1700Fax510-745-0493Employees86Year Founded2007Price Target and Rating Average Stock Price Forecast$6.25 High Stock Price Forecast$8.00 Low Stock Price Forecast$3.00 Forecasted Upside/Downside+77.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-67,210,000.00 Net Margins-104.52% Pretax Margin-104.49% Return on Equity-76.72% Return on Assets-38.58% Debt Debt-to-Equity RatioN/A Current Ratio2.65 Quick Ratio2.57 Sales & Book Value Annual Sales$63.06 million Price / Sales11.97 Cash FlowN/A Price / Cash FlowN/A Book Value$0.58 per share Price / Book6.07Miscellaneous Outstanding Shares214,462,000Free Float202,667,000Market Cap$754.91 million OptionableOptionable Beta1.21 Social Links Key ExecutivesMike RaabPresident, Chief Executive Officer & DirectorJustin A. RenzChief Financial, Operations Officer & TreasurerLaura A. WilliamsChief Medical OfficerElizabeth GrammerSecretary, Chief Legal & Administrative OfficerDavid P. RosenbaumChief Development OfficerKey CompetitorsRAPT TherapeuticsNASDAQ:RAPTARS PharmaceuticalsNASDAQ:SPRYAmneal PharmaceuticalsNYSE:AMRXLyell ImmunopharmaNASDAQ:LYELArcturus TherapeuticsNASDAQ:ARCTView All CompetitorsInsiders & InstitutionsPrelude Capital Management LLCBought 17,933 shares on 6/1/2023Ownership: 0.008%Michael RaabSold 11,357 sharesTotal: $41,453.05 ($3.65/share)Justin A RenzSold 2,873 sharesTotal: $10,486.45 ($3.65/share)Robert Ora FelschSold 1,046 sharesTotal: $3,817.90 ($3.65/share)Ameriprise Financial Inc.Bought 10,213 shares on 5/22/2023Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions ARDX Stock - Frequently Asked Questions Should I buy or sell Ardelyx stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ardelyx in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ARDX shares. View ARDX analyst ratings or view top-rated stocks. What is Ardelyx's stock price forecast for 2023? 3 brokerages have issued 1 year price targets for Ardelyx's shares. Their ARDX share price forecasts range from $3.00 to $8.00. On average, they anticipate the company's share price to reach $6.25 in the next twelve months. This suggests a possible upside of 77.6% from the stock's current price. View analysts price targets for ARDX or view top-rated stocks among Wall Street analysts. How have ARDX shares performed in 2023? Ardelyx's stock was trading at $2.85 at the start of the year. Since then, ARDX shares have increased by 23.5% and is now trading at $3.52. View the best growth stocks for 2023 here. Are investors shorting Ardelyx? Ardelyx saw a decline in short interest in the month of May. As of May 15th, there was short interest totaling 16,690,000 shares, a decline of 8.5% from the April 30th total of 18,240,000 shares. Based on an average daily volume of 7,350,000 shares, the short-interest ratio is presently 2.3 days. View Ardelyx's Short Interest. When is Ardelyx's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our ARDX earnings forecast. How were Ardelyx's earnings last quarter? Ardelyx, Inc. (NASDAQ:ARDX) announced its quarterly earnings results on Wednesday, May, 3rd. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.02. The biopharmaceutical company had revenue of $11.37 million for the quarter, compared to analysts' expectations of $10.08 million. Ardelyx had a negative net margin of 104.52% and a negative trailing twelve-month return on equity of 76.72%. What ETFs hold Ardelyx's stock? ETFs with the largest weight of Ardelyx (NASDAQ:ARDX) stock in their portfolio include Invesco DWA Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Invesco Nasdaq Future Gen 200 ETF (QQQS), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), ProShares Ultra Nasdaq Biotechnology (BIB), What other stocks do shareholders of Ardelyx own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ardelyx investors own include Micron Technology (MU), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Rigel Pharmaceuticals (RIGL), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), TherapeuticsMD (TXMD) and Advanced Micro Devices (AMD). What is Ardelyx's stock symbol? Ardelyx trades on the NASDAQ under the ticker symbol "ARDX." Who are Ardelyx's major shareholders? Ardelyx's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (7.09%), BlackRock Inc. (1.73%), Renaissance Technologies LLC (1.46%), Two Sigma Investments LP (1.33%), Price T Rowe Associates Inc. MD (1.19%) and Bank of America Corp DE (0.97%). Insiders that own company stock include David M Mott, David P Rosenbaum, Elizabeth A Grammer, Forest Baskett, Jeffrey W Jacobs, Jeffrey W Jacobs, Justin A Renz, Laura A Williams, Michael Raab, Robert Blanks, Robert Ora Felsch, Scott D Sandell and Susan Rodriguez. View institutional ownership trends. How do I buy shares of Ardelyx? Shares of ARDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ardelyx's stock price today? One share of ARDX stock can currently be purchased for approximately $3.52. How much money does Ardelyx make? Ardelyx (NASDAQ:ARDX) has a market capitalization of $754.91 million and generates $63.06 million in revenue each year. The biopharmaceutical company earns $-67,210,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis. How can I contact Ardelyx? Ardelyx's mailing address is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. The official website for the company is www.ardelyx.com. The biopharmaceutical company can be reached via phone at (510) 745-1700, via email at investor@ardelyx.com, or via fax at 510-745-0493. This page (NASDAQ:ARDX) was last updated on 6/4/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ardelyx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.